Catherine Avery Investment Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.91M Buy
119,907
+15,044
+14% +$864K 3.02% 8
2026
Q1
$6.36M Buy
104,863
+12,024
+13% +$701K 2.85% 13
2025
Q4
$5.01M Buy
92,839
+183
+0.2% +$8.8K 3% 8
2025
Q3
$4.18M Buy
92,656
+17,675
+24% +$825K 2.69% 20
2025
Q2
$3.47M Buy
74,981
+8,713
+13% +$428K 2.64% 18
2025
Q1
$4.04M Buy
66,268
+4,988
+8% +$291K 3.62% 4
2024
Q4
$3.47M Buy
+61,280
New +$3.42M 3.06% 6

Other funds holding BMY

Catherine Avery Investment Management's BMY Position: Q2 2026 in Review

Catherine Avery Investment Management increased its Bristol-Myers Squibb (BMY) stake by 14% in Q2 2026, buying an estimated $864K and bringing the position to 119,907 shares worth $6.91M. The position accounts for 3.02% of the portfolio, ranked #8.

Catherine Avery Investment Management first reported a position in BMY in Q4 2024 and has held it in 7 quarters since. 2,511 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Catherine Avery Investment Management held 119,907 shares of Bristol-Myers Squibb worth $6.91M as of Q2 2026.
  • Catherine Avery Investment Management bought 15,044 Bristol-Myers Squibb shares in Q2 2026, an estimated $864K.
  • Bristol-Myers Squibb made up 3.02% of Catherine Avery Investment Management's portfolio in Q2 2026, its #8 holding.
  • Catherine Avery Investment Management first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 7 quarters since.
  • 2,511 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Catherine Avery Investment Management's 13F filing for Q2 2026, filed 27 Jul 2026.